Monitoring of minimal residual disease in chronic myeloid leukemia.
about
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.Where medicine, business, and public policy intersect.BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.Magnetic Nanoparticles PCR Enzyme-Linked Gene Assay for Quantitative Detection of BCR/ABL Fusion Gene in Chronic Myelogenous Leukemia.
P2860
Monitoring of minimal residual disease in chronic myeloid leukemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Monitoring of minimal residual disease in chronic myeloid leukemia.
@ast
Monitoring of minimal residual disease in chronic myeloid leukemia.
@en
type
label
Monitoring of minimal residual disease in chronic myeloid leukemia.
@ast
Monitoring of minimal residual disease in chronic myeloid leukemia.
@en
prefLabel
Monitoring of minimal residual disease in chronic myeloid leukemia.
@ast
Monitoring of minimal residual disease in chronic myeloid leukemia.
@en
P1476
Monitoring of minimal residual disease in chronic myeloid leukemia.
@en
P2093
Timothy Hughes
P304
657-70, ix-x
P356
10.1016/J.HOC.2004.03.010
P577
2004-06-01T00:00:00Z